Nigel Brooksby named as ABPI president designate
Nigel Brooksby, chairman and md of sanofi-aventis in the UK, will become the new president of the ABPI (Association of the British Pharmaceutical Industry) in April 2006.
Nigel Brooksby, chairman and md of sanofi-aventis in the UK, will become the new president of the ABPI (Association of the British Pharmaceutical Industry) in April 2006.
A graduate in biological sciences in 1973, he joined Sanofi in 1992, is chairman of the ABPI's Commercial Affairs Group and has been a member of the ABPI Board of Management since 1999. He will take the reigns from Vincent Lawton of Merck Sharpe & Dohme (UK) and will serve a two-year term.
'With health services across Europe facing difficult times, it is essential that the [UK] pharmaceutical industry works in close co-operation with the [UK] Government to ensure that patients get the best possible treatment,' said Brooksby.
'Health provision is a complex interaction involving patients, doctors, hospitals, clinics, medicines and other therapies. The pharmaceutical industry must work in partnership with all those involved, especially patients, to ensure that the treatment achieved is the best, most appropriate for the individual concerned.'
Brooksby went on to say that new Government priorities - in the Government's words, 'a programme of investment and reforms [to] improve the nation's health and wealth by making the UK a world-class environment for medical research, development and innovation' - the modernisation of the NHS and developments in innovative medicines called for the 'break[ing] down of communication barriers to ensure that the voice of all those taking part in the provision of healthcare is heard'.